{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T11:21:37Z","timestamp":1753356097239,"version":"3.37.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"DOI":"10.1007\/s00432-025-06089-x","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T03:38:22Z","timestamp":1737603502000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged\u2009\u2265\u200975\u00a0years) with non-small cell lung cancer"],"prefix":"10.1007","volume":"151","author":[{"given":"Satoshi","family":"Endo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3097-4255","authenticated-orcid":false,"given":"Hisao","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuto","family":"Mouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kasumi","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Masaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Miura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayako","family":"Shiono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ou","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoichi","family":"Kaira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiko","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kagamu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"6089_CR1","doi-asserted-by":"publisher","first-page":"e286","DOI":"10.1016\/j.cllc.2020.01.001","volume":"21","author":"T Ahmed","year":"2020","unstructured":"Ahmed T, Lycan T, Dothard A et al (2020) Performance status and age as predictors of immunotherapy outcomes in advanced non-small-cell lung cancer. Clin Lung Cancer 21:e286\u2013e293. https:\/\/doi.org\/10.1016\/j.cllc.2020.01.001","journal-title":"Clin Lung Cancer"},{"key":"6089_CR2","doi-asserted-by":"publisher","first-page":"e679","DOI":"10.1634\/theoncologist.2019-0299","volume":"25","author":"H Akamatsu","year":"2020","unstructured":"Akamatsu H, Murakami E, Oyanagi J et al (2020) Immune-related adverse events by immune checkpoint inhibitors significantly predict durable efficacy even in responders with advanced non-small cell lung cancer. Oncologist 25:e679\u2013e683. https:\/\/doi.org\/10.1634\/theoncologist.2019-0299","journal-title":"Oncologist"},{"key":"6089_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-001079","volume":"5","author":"L Albiges","year":"2020","unstructured":"Albiges L, Tannir NM, Burotto M et al (2020) Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open 5:e001079. https:\/\/doi.org\/10.1136\/esmoopen-2020-001079","journal-title":"ESMO Open"},{"key":"6089_CR4","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.21873\/invivo.13324","volume":"37","author":"J Blazek","year":"2023","unstructured":"Blazek J, Hosek P, Hrabcova K et al (2023) Serious immune-related adverse events are associated with greater efficacy of nivolumab therapy against non-small cell lung cancer. In Vivo 37:2229\u20132236","journal-title":"In Vivo"},{"key":"6089_CR5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/imr.13262","volume":"318","author":"SM Blum","year":"2023","unstructured":"Blum SM, Rouhani SJ, Sullivan RJ (2023) Effects of immune-related adverse events (irAEs) and their treatment on antitumor immune responses. Immunol Rev 318:167\u2013178. https:\/\/doi.org\/10.1111\/imr.13262","journal-title":"Immunol Rev"},{"key":"6089_CR6","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","volume":"28","author":"JR Brahmer","year":"2010","unstructured":"Brahmer JR, Drake CG, Wollner I et al (2010) Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28:3167\u20133175. https:\/\/doi.org\/10.1200\/JCO.2009.26.7609","journal-title":"J Clin Oncol"},{"key":"6089_CR7","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1200\/JCO.22.01503","volume":"41","author":"JR Brahmer","year":"2023","unstructured":"Brahmer JR, Lee JS, Ciuleanu TE et al (2023) Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer in CheckMate 227. J Clin Oncol 41:1200\u20131212. https:\/\/doi.org\/10.1200\/JCO.22.01503","journal-title":"J Clin Oncol"},{"key":"6089_CR8","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/annonc\/mdv623","volume":"27","author":"S Champiat","year":"2016","unstructured":"Champiat S, Lambotte O, Barreau E et al (2016) Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 27:559\u2013574. https:\/\/doi.org\/10.1093\/annonc\/mdv623","journal-title":"Ann Oncol"},{"key":"6089_CR9","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.lungcan.2020.04.027","volume":"145","author":"FG Dall\u2019Olio","year":"2020","unstructured":"Dall\u2019Olio FG, Maggio I, Massucci M, Mollica V, Fragomeno B, Ardizzoni A (2020) ECOG performance status >\/=2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-a systematic review and meta-analysis of real world data. Lung Cancer 145:95\u2013104. https:\/\/doi.org\/10.1016\/j.lungcan.2020.04.027","journal-title":"Lung Cancer"},{"key":"6089_CR10","doi-asserted-by":"publisher","first-page":"950","DOI":"10.4049\/jimmunol.1401686","volume":"194","author":"R Das","year":"2015","unstructured":"Das R, Verma R, Sznol M et al (2015) Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol 194:950\u2013959. https:\/\/doi.org\/10.4049\/jimmunol.1401686","journal-title":"J Immunol"},{"key":"6089_CR11","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1200\/JCO.2009.25.4052","volume":"28","author":"AJ Davidoff","year":"2010","unstructured":"Davidoff AJ, Tang M, Seal B, Edelman MJ (2010) Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 28:2191\u20132197. https:\/\/doi.org\/10.1200\/JCO.2009.25.4052","journal-title":"J Clin Oncol"},{"key":"6089_CR12","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa2111380","volume":"386","author":"Y Doki","year":"2022","unstructured":"Doki Y, Ajani JA, Kato K et al (2022) Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med 386:449\u2013462. https:\/\/doi.org\/10.1056\/NEJMoa2111380","journal-title":"N Engl J Med"},{"key":"6089_CR13","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.21873\/anticanres.17122","volume":"44","author":"N Ebi","year":"2024","unstructured":"Ebi N, Inoue H, Igata F et al (2024) Clinical association between immune-related adverse events and treatment efficacy in patients with non-small-cell lung cancer treated with Nivolumab-Ipilimumab-based therapy. Anticancer Res 44:3087\u20133095","journal-title":"Anticancer Res"},{"key":"6089_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"6089_CR15","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1200\/JCO.2013.49.5283","volume":"31","author":"A Giobbie-Hurder","year":"2013","unstructured":"Giobbie-Hurder A, Gelber RD, Regan MM (2013) Challenges of guarantee-time bias. J Clin Oncol 31:2963\u20132969. https:\/\/doi.org\/10.1200\/JCO.2013.49.5283","journal-title":"J Clin Oncol"},{"key":"6089_CR16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","volume":"11","author":"P Goldstraw","year":"2016","unstructured":"Goldstraw P, Chansky K, Crowley J et al (2016) The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 11:39\u201351. https:\/\/doi.org\/10.1016\/j.jtho.2015.09.009","journal-title":"J Thorac Oncol"},{"key":"6089_CR17","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","volume":"4","author":"K Haratani","year":"2018","unstructured":"Haratani K, Hayashi H, Chiba Y et al (2018) Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol 4:374\u2013378. https:\/\/doi.org\/10.1001\/jamaoncol.2017.2925","journal-title":"JAMA Oncol"},{"key":"6089_CR18","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann MD, Paz-Ares L, Caro RB et al (2019) Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med 381:2020\u20132031. https:\/\/doi.org\/10.1056\/NEJMoa1910231","journal-title":"N Engl J Med"},{"key":"6089_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102134","volume":"92","author":"S Hussaini","year":"2021","unstructured":"Hussaini S, Chehade R, Boldt RG, Raphael J, Blanchette P, Vareki SM, Fernandes R (2021) Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors: a systematic review and meta-analysis. Cancer Treat Rev 92:102134. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102134","journal-title":"Cancer Treat Rev"},{"key":"6089_CR20","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s00432-019-03072-1","volume":"146","author":"H Imai","year":"2020","unstructured":"Imai H, Wasamoto S, Yamaguchi O et al (2020) Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged \u2265 75 years) with non-small cell lung cancer. J Cancer Res Clin Oncol 146:457\u2013466. https:\/\/doi.org\/10.1007\/s00432-019-03072-1","journal-title":"J Cancer Res Clin Oncol"},{"key":"6089_CR21","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","volume":"19","author":"DB Johnson","year":"2022","unstructured":"Johnson DB, Nebhan CA, Moslehi JJ, Balko JM (2022) Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol 19:254\u2013267. https:\/\/doi.org\/10.1038\/s41571-022-00600-w","journal-title":"Nat Rev Clin Oncol"},{"key":"6089_CR22","doi-asserted-by":"publisher","first-page":"e791","DOI":"10.1016\/S2666-7568(21)00255-5","volume":"2","author":"Y Kogure","year":"2021","unstructured":"Kogure Y, Iwasawa S, Saka H et al (2021) Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (Capital): a randomised, multicentre, open-label, phase 3 trial. Lancet Healthy Longev 2:e791\u2013e800. https:\/\/doi.org\/10.1016\/S2666-7568(21)00255-5","journal-title":"Lancet Healthy Longev"},{"key":"6089_CR23","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1200\/JCO.2006.06.1044","volume":"24","author":"S Kudoh","year":"2006","unstructured":"Kudoh S, Takeda K, Nakagawa K et al (2006) Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 24:3657\u20133663. https:\/\/doi.org\/10.1200\/JCO.2006.06.1044","journal-title":"J Clin Oncol"},{"issue":"24","key":"6089_CR24","doi-asserted-by":"publisher","first-page":"00264","DOI":"10.1016\/S2213-2600(24)00264-9","volume":"S2213\u20132600","author":"H Lena","year":"2024","unstructured":"Lena H, Greillier L, Cropet C et al (2024) Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged \u226570 years or with an ECOG performance status of 2 (GFPC 08\u20132015 ENERGY): a randomised, open-label, phase 3 study. Lancet Respir Med S2213\u20132600(24):00264\u201300269. https:\/\/doi.org\/10.1016\/S2213-2600(24)00264-9","journal-title":"Lancet Respir Med"},{"key":"6089_CR25","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3322\/caac.21349","volume":"66","author":"KD Miller","year":"2016","unstructured":"Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Jemal A (2016) Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 66:271\u2013289. https:\/\/doi.org\/10.3322\/caac.21349","journal-title":"CA Cancer J Clin"},{"key":"6089_CR26","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.lungcan.2021.08.015","volume":"161","author":"K Morimoto","year":"2021","unstructured":"Morimoto K, Yamada T, Yokoi T et al (2021a) Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer. Lung Cancer 161:26\u201333. https:\/\/doi.org\/10.1016\/j.lungcan.2021.08.015","journal-title":"Lung Cancer"},{"key":"6089_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.630136","volume":"11","author":"K Morimoto","year":"2021","unstructured":"Morimoto K, Yamada T, Takumi C et al (2021b) Immune-related adverse events are associated with clinical benefit in patients with non-small-cell lung cancer treated with immunotherapy plus chemotherapy: a retrospective study. Front Oncol 11:630136. https:\/\/doi.org\/10.3389\/fonc.2021.630136","journal-title":"Front Oncol"},{"key":"6089_CR28","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.lungcan.2019.07.004","volume":"135","author":"K Nosaki","year":"2019","unstructured":"Nosaki K, Saka H, Hosomi Y et al (2019) Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung Cancer 135:188\u2013195. https:\/\/doi.org\/10.1016\/j.lungcan.2019.07.004","journal-title":"Lung Cancer"},{"key":"6089_CR29","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.6828","volume":"6","author":"I Okamoto","year":"2020","unstructured":"Okamoto I, Nokihara H, Nomura S et al (2020) Comparison of carboplatin plus pemetrexed followed by maintenance pemetrexed with docetaxel monotherapy in elderly patients with advanced nonsquamous non-small cell lung cancer: a Phase 3 randomized clinical trial. JAMA Oncol 6:e196828. https:\/\/doi.org\/10.1001\/jamaoncol.2019.6828","journal-title":"JAMA Oncol"},{"key":"6089_CR30","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.1200\/JCO.2016.67.7088","volume":"34","author":"HH Pang","year":"2016","unstructured":"Pang HH, Wang X, Stinchcombe TE et al (2016) Enrollment trends and disparity among patients with lung cancer in national clinical trials, 1990 to 2012. J Clin Oncol 34:3992\u20133999. https:\/\/doi.org\/10.1200\/JCO.2016.67.7088","journal-title":"J Clin Oncol"},{"key":"6089_CR31","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jtho.2022.08.014","volume":"18","author":"LG Paz-Ares","year":"2023","unstructured":"Paz-Ares LG, Ciuleanu TE, Pluzanski A et al (2023) Safety of first-line nivolumab plus ipilimumab in patients with metastatic NSCLC: a pooled analysis of CheckMate 227, CheckMate 568, and CheckMate 817. J Thorac Oncol 18:79\u201392. https:\/\/doi.org\/10.1016\/j.jtho.2022.08.014","journal-title":"J Thorac Oncol"},{"key":"6089_CR32","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","volume":"33","author":"S Peters","year":"2022","unstructured":"Peters S, Scherpereel A, Cornelissen R et al (2022) First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol 33:488\u2013499. https:\/\/doi.org\/10.1016\/j.annonc.2022.01.074","journal-title":"Ann Oncol"},{"key":"6089_CR33","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40266-017-0479-1","volume":"34","author":"K Poropatich","year":"2017","unstructured":"Poropatich K, Fontanarosa J, Samant S, Sosman JA, Zhang B (2017) Cancer immunotherapies: are they as effective in the elderly? Drugs Aging 34:567\u2013581. https:\/\/doi.org\/10.1007\/s40266-017-0479-1","journal-title":"Drugs Aging"},{"key":"6089_CR34","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/S0140-6736(11)60780-0","volume":"378","author":"E Quoix","year":"2011","unstructured":"Quoix E, Zalcman G, Oster JP et al (2011) Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 378:1079\u20131088. https:\/\/doi.org\/10.1016\/S0140-6736(11)60780-0","journal-title":"Lancet"},{"key":"6089_CR35","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","volume":"16","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Mazi\u00e8res J, Planchard D et al (2015) Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 16:257\u2013265. https:\/\/doi.org\/10.1016\/S1470-2045(15)70054-9","journal-title":"Lancet Oncol"},{"key":"6089_CR36","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1097\/PAI.0000000000000408","volume":"24","author":"C Roach","year":"2016","unstructured":"Roach C, Zhang N, Corigliano E, Jansson M, Toland G, Ponto G, Dolled-Filhart M, Emancipator K, Stanforth D, Kulangara K (2016) Development of a companion diagnostic PD-L1 immunohistochemistry assay for pembrolizumab therapy in non-small-cell lung cancer. Appl Immunohistochem Mol Morphol 24:392\u2013397. https:\/\/doi.org\/10.1097\/PAI.0000000000000408","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"6089_CR37","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1097\/JTO.0b013e31827e2145","volume":"8","author":"AG Sacher","year":"2013","unstructured":"Sacher AG, Le LW, Leighl NB, Coate LE (2013) Elderly patients with advanced NSCLC in phase III clinical trials: are the elderly excluded from practice-changing trials in advanced NSCLC? J Thorac Oncol 8:366\u2013368. https:\/\/doi.org\/10.1097\/JTO.0b013e31827e2145","journal-title":"J Thorac Oncol"},{"doi-asserted-by":"publisher","unstructured":"Sculier JP, Chansky K, Crowley JJ, Van Meerbeeck J, Goldstraw P (2008) The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition. J Thorac Oncol 3:457\u2013466. https:\/\/doi.org\/10.1097\/JTO.0b013e31816de2b8","key":"6089_CR38","DOI":"10.1097\/JTO.0b013e31816de2b8"},{"key":"6089_CR39","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41577-020-0275-8","volume":"20","author":"P Sharma","year":"2020","unstructured":"Sharma P, Allison JP (2020) Dissecting the mechanisms of immune checkpoint therapy. Nat Rev Immunol 20:75\u201376. https:\/\/doi.org\/10.1038\/s41577-020-0275-8","journal-title":"Nat Rev Immunol"},{"key":"6089_CR40","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/1745-6215-13-138","volume":"13","author":"S Singh","year":"2012","unstructured":"Singh S, Loke YK (2012) Drug safety assessment in clinical trials: methodological challenges and opportunities. Trials 13:138. https:\/\/doi.org\/10.1186\/1745-6215-13-138","journal-title":"Trials"},{"key":"6089_CR41","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41573-021-00259-5","volume":"21","author":"RJ Sullivan","year":"2022","unstructured":"Sullivan RJ, Weber JS (2022) Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies. Nat Rev Drug Discov 21:495\u2013508. https:\/\/doi.org\/10.1038\/s41573-021-00259-5","journal-title":"Nat Rev Drug Discov"},{"key":"6089_CR42","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"6089_CR43","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443\u20132454. https:\/\/doi.org\/10.1056\/NEJMoa1200690","journal-title":"N Engl J Med"},{"key":"6089_CR44","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1001\/jamaoncol.2023.6277","volume":"10","author":"Y Tsukita","year":"2024","unstructured":"Tsukita Y, Tozuka T, Kushiro K et al (2024) Immunotherapy or chemoimmunotherapy in older adults with advanced non-small cell lung cancer. JAMA Oncol 10:439\u2013447. https:\/\/doi.org\/10.1001\/jamaoncol.2023.6277","journal-title":"JAMA Oncol"},{"key":"6089_CR45","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1158\/2326-6066.CIR-14-0040","volume":"2","author":"C Wang","year":"2014","unstructured":"Wang C, Thudium KB, Han M et al (2014) In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res 2:846\u2013856. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0040","journal-title":"Cancer Immunol Res"},{"key":"6089_CR46","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1007\/s00262-021-03115-y","volume":"71","author":"W Wang","year":"2022","unstructured":"Wang W, Gu X, Wang L et al (2022) The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study. Cancer Immunol Immunother 71:1693\u20131703. https:\/\/doi.org\/10.1007\/s00262-021-03115-y","journal-title":"Cancer Immunol Immunother"},{"key":"6089_CR47","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2169\/internalmedicine.3649-24","volume":"64","author":"S Wasamoto","year":"2025","unstructured":"Wasamoto S, Imai H, Tsuda T et al (2025) Efficacy and safety of first-line pembrolizumab plus platinum and pemetrexed in elderly patients with non-squamous non-small-cell lung cancer. Intern Med 64:55\u201364. https:\/\/doi.org\/10.2169\/internalmedicine.3649-24","journal-title":"Intern Med"},{"key":"6089_CR48","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei SC, Duffy CR, Allison JP (2018) Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 8:1069\u20131086. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0367","journal-title":"Cancer Discov"},{"key":"6089_CR49","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1200\/JCO.21.02229","volume":"40","author":"JD Wolchok","year":"2022","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R et al (2022) Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol 40:127\u2013137. https:\/\/doi.org\/10.1200\/JCO.21.02229","journal-title":"J Clin Oncol"},{"key":"6089_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.807575","volume":"13","author":"Z Yang","year":"2022","unstructured":"Yang Z, Chen Y, Wang Y, Hu M, Qian F, Zhang Y, Zhang B, Zhang W, Han B (2022) Pembrolizumab plus chemotherapy versus chemotherapy monotherapy as a first-line treatment in elderly patients (>\/=75 years old) with non-small-cell lung cancer. Front Immunol 13:807575. https:\/\/doi.org\/10.3389\/fimmu.2022.807575","journal-title":"Front Immunol"},{"key":"6089_CR51","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12916-020-01549-2","volume":"18","author":"X Zhou","year":"2020","unstructured":"Zhou X, Yao Z, Yang H, Liang N, Zhang X, Zhang F (2020) Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med 18:87. https:\/\/doi.org\/10.1186\/s12916-020-01549-2","journal-title":"BMC Med"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06089-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-025-06089-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06089-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T07:16:29Z","timestamp":1738998989000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-025-06089-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["6089"],"URL":"https:\/\/doi.org\/10.1007\/s00432-025-06089-x","relation":{},"ISSN":["1432-1335"],"issn-type":[{"type":"electronic","value":"1432-1335"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"assertion":[{"value":"4 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Review Board of the International Medical Center, Saitama Medical University (number 2023-080).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The need for informed consent was waived by the institutional review boards of the participating institutions owing to the retrospective nature of the study. However, an opportunity to refuse participation through the opt-out method was provided.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"43"}}